Shenzhen Bioeasy Biotechnology Co., Ltd. Class A

Shenzhen Bioeasy Biotechnology Co., Ltd. Class A

SSZSE:300942
5.45
CNY
-0.12
(-2.15%)
-0.07EPS
2.69BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.69
1.89
2.08
0.67
0.71
1.52
1.74
0.63
0.52
0.57
0.69
Basic EPS, GAAP
2.34
0.54
0.75
0.26
0.18
0.6
0.21
-0.46
0.04
0.03
-0.08
Free Cash Flow per Basic Share
2.72
0.18
0.48
0.12
-0.05
0.45
-0.06
-0.41
-0.33
0.05
- -
Dividend per Share
- -
0.38
0.28
0.02
0.12
0.05
0.25
0.03
0.01
0.03
0.04
Book Value per Share
1.09
2.27
4.28
1.47
1.53
2.36
2.41
2.12
2.17
2.23
2.14
Tangible Book Value per Share
1.09
2.26
4.26
1.46
1.4
2.25
2.3
2.01
2.07
2.14
2.05
Basic Weighted Avg Shares
10
73
99
355
364
394
395
402
428
458
405
Sales/Revenue/Turnover
87
138
205
239
258
598
687
254
224
263
281
Operating Margin (%)
19.23
33.14
40.97
40.93
35.81
44.84
20.05
-26.31
18.15
10.04
5.07
Depreciation Expense
3
4
4
5
6
24
30
33
21
30
- -
Net Income, GAAP
23
39
74
92
65
237
83
-185
17
14
-32
Effective Tax Rate (%)
13.28
10.99
12.71
12.97
11.49
11.78
12.88
- -
15.59
- -
- -
Profit Margin (%)
26.93
28.5
36.08
38.59
25.32
39.58
12.08
-72.77
7.63
5.22
-11.29
Working Capital
72
123
227
502
436
741
475
601
600
657
671
LT Debt
- -
- -
- -
- -
42
27
96
351
426
413
440
Total Equity
55
115
223
528
549
947
965
849
870
908
873
Return on Invested Capital (%)
- -
45.21
45.12
25.17
11.91
29.72
8.27
- -
1.4
- -
- -
Return on Capital (%)
- -
46.3
43.86
24.59
11.63
30
8.38
- -
2.61
- -
- -
Return on Common Equity (%)
- -
46.25
43.83
24.58
12.15
31.66
8.69
-20.39
1.99
1.55
-3.66

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
25
25
13
LT Borrowings
437
438
440
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
405
405
405
Market Capitalization
3,403
2,341
2,694

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
798
794
775
Cash, Cash Equivalents & STI
600
584
544
Accounts Receivable, Net
102
115
125
Inventories
62
65
76
Total Current Liabilities
109
120
104
Payables & Accruals
- -
- -
- -
ST Debt
25
25
13
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.83%
4.3%
Free Cash Flow
- -
-137.09%
-115%
Net Income, GAAP
- -
-51.08%
-19.71%
Sales/Revenue/Turnover
- -
17.75%
17.38%
Total Cash Common Dividend
- -
82.29%
159.63%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36
67
54
66
224
2025
49
60
- -
78
263
2026
58
71
75
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
0.01
0.01
0.03
0.04
2025
-0.01
0.01
- -
-0.01
0.03
2026
-0.03
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
0.02
- -
- -
0.03
2026
- -
0.03
0.01
- -
- -

Company Description

CEO
Zhao Li Xiao
Full Time Employees
542
Sector
Health technology
Industry
Medical specialties
Address
A101, Building 2 Shenzhen GD China 518126
IPO Date
Feb 9, 2021
Business
Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ) develops, manufactures, and sells rapid testing instruments, reagents, and related services primarily for food safety, animal health diagnostics, clinical applications, and public safety detection. The company offers an extensive range of products including colloidal gold immunochromatographic test strips and ELISA kits for detecting antibiotics, mycotoxins such as aflatoxin and zearalenone, pesticides, and adulterants in dairy products like milk; cereals and feed; fruits and vegetables; meat and seafood; honey and eggs; veterinary diagnostics for ruminants, swine, avian, and companion animals such as brucella antibody, African swine fever virus, and pregnancy rapid tests; clinical POCT solutions for infectious diseases including coronavirus, tropical infections, gastrointestinal pathogens, and drug abuse screening; as well as fluorescence PCR kits, nucleic acid extraction kits, portable analyzers, pretreatment columns, and certified reference materials. Founded in 2007 and headquartered at No. 101, Liuxian Yirui Biological Building in Shenzhen's Bao'an District, China, the company operates globally across more than 60 countries with approximately 480 employees, serving food production, processing, agriculture, breeding, laboratories, and healthcare sectors. Its wholly-owned subsidiary Shenzhen Anieasy Biotechnology Co., Ltd., established in January 2022, bolsters animal health diagnostics with advanced platforms in immunodiagnostics, molecular diagnostics, and mRNA vaccine technologies. Recent developments include Wang Tianyi's completion of a 6.59% stake acquisition in 2025, approval of a final cash dividend for fiscal year 2024 payable in May 2025, ongoing expansion of pet infectious disease detection products into hospitals, new product launches such as fluorescence quantitative rapid tests for aflatoxin M1 in milk (15-150 ppt) and multi-residue antibiotic kits like 4IN1 BSCT and Amino 3IN1 GSN, participation in international events like IAFP 2024, and sustained R&D with over 110 patents and 200 team members focusing on one-stop food safety ecosystems.